Chromos enters into loan and lending arrangements



    BURNABY, BC, March 20 /CNW/ - Chromos Molecular Systems Inc. ("Chromos")
(TSX:CHR) announced today that the Company entered into a secured, convertible
debenture agreement to borrow $400,000. The proceeds of the loan are to be
used to fund expenses associated with the preparation of delinquent continuous
disclosure documents and maintaining the integrity of the remaining assets of
the Company. The principal and interest, at 12% per annum, are due and payable
on June 30, 2008. The debenture holder has the right, upon notice, to convert
all or part of the principal and unpaid interest into common shares of the
Company at the conversion price of $0.03 per share. The Company also entered
into a Pledge of Securities agreement as part of the security arrangement with
the debenture holder for the Company's common shares in Agrisoma Biosciences
Inc. ("Agrisoma"). As collateral for the convertible debenture, the Company
provided the debenture holder a general security agreement providing a charge
over all the Company's assets. Prior to entering into this transaction, the
Company obtained a partial revocation of the existing cease trade order from
the B.C. Securities Commission.
    The Company has also entered into a convertible promissory note agreement
(the "Agrisoma Note") to loan $500,000 to Agrisoma. Of this amount,
$118,000 was funded in-kind by Chromos by offsetting it against $118,000 of
amounts due from Agrisoma for license fees, rent and other services, and
patent cost recoveries. The remaining $382,000 was funded in cash by Chromos
to Agrisoma. The cash advanced to Agrisoma is to be used for operations. The
secured Agrisoma Note, which bears interest of 15% per annum, is due the
earlier of: June 30, 2008 and certain specified events. As collateral for the
Agrisoma Note, Agrisoma provided the Company with a general security agreement
providing a charge over all of Agrisoma's assets.

    Risks and Uncertainties

    Certain of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Chromos, or industry results, to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements.
    To the extent possible, management implements strategies to reduce or
mitigate the risks and uncertainties associated with Chromos' operations.
Operating risks include (i) the continued availability of capital to finance
Chromos' activities; (ii) Chromos' limited cash position, and (iii) Chromos'
limited operations.





For further information:

For further information: Jeff Charpentier, Vice President, Finance and
CFO, Tel: (604) 415-7132, Email:jcharpentier@chromos.com; Alistair Duncan,
President & CEO, Tel: (604) 415-7121, Email: aduncan@chromos.com, Website:
www.chromos.com

Organization Profile

CHROMOS MOLECULAR SYSTEMS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890